Publish Date
30 Nov -0001
<![CDATA[Abstract. Chronic kidney disease (CKD) is commonly associated with anemia due to decreased erythropoietin production by the kidneys, resulting in impaired erythropoiesis and reduced hemoglobin, hematocrit, and erythrocyte levels. This study aimed to evaluate the effectiveness of erythropoietin-containing combination therapy based on changes in hemoglobin, hematocrit, and erythrocyte levels in CKD patients undergoing hemodialysis at Bandung Kiwari Regional Hospital. A descriptive observational study with a retrospective approach was conducted using medical records of 53 patients who met the inclusion and exclusion criteria. Data were analyzed descriptively, while statistical analyses were performed using the Shapiro–Wilk normality test followed by the Wilcoxon test. The results showed that 62% of patients achieved the target hemoglobin response of 0.5–1.5 g/dL. The combination of epoetin alfa and folic acid, as well as epoetin alfa, folic acid, and vitamin B12, significantly increased hemoglobin, hematocrit, and erythrocyte levels (p<0.05). In conclusion, erythropoietin-containing combination therapy was effective in improving hemoglobin, hematocrit, and erythrocyte levels in CKD patients undergoing hemodialysis. Abstrak. Gagal ginjal kronis (GGK) sering disertai anemia akibat penurunan produksi eritropoietin oleh ginjal yang mengganggu proses eritropoiesis sehingga menyebabkan penurunan kadar hemoglobin, hematokrit, dan eritrosit. Penelitian ini bertujuan mengevaluasi efektivitas terapi kombinasi yang mengandung eritropoietin berdasarkan perubahan kadar hemoglobin, hematokrit, dan eritrosit pada pasien gagal ginjal kronis yang menjalani hemodialisis di RSUD Bandung Kiwari periode Januari–Desember 2025. Penelitian ini merupakan penelitian observasional deskriptif dengan pendekatan retrospektif menggunakan data rekam medis 53 pasien yang memenuhi kriteria inklusi dan eksklusi. Data dianalisis secara deskriptif, sedangkan analisis statistik dilakukan menggunakan uji normalitas Shapiro–Wilk dan uji Wilcoxon. Hasil penelitian menunjukkan bahwa 62% pasien mencapai target respons peningkatan hemoglobin sebesar 0,5–1,5 g/dL. Terapi kombinasi epoetin alfa dan asam folat serta kombinasi epoetin alfa, asam folat, dan vitamin B12 meningkatkan kadar hemoglobin, hematokrit, dan eritrosit secara signifikan (p<0,05). Disimpulkan bahwa terapi kombinasi yang mengandung eritropoietin efektif meningkatkan kadar hemoglobin, hematokrit, dan eritrosit pada pasien gagal ginjal kronis yang menjalani hemodialisis.]]>
Copyrights © 0000
